The 3rd ISCC
December 3, 1998
Nagai Memorial Hall
Program
9:00-9:05
Haruo Sugano (Cancer Chemotherapy Center, Japan)
Welcome and Introduction
1. New Strategy for Drug Discovery
Chairperson: Edward A. Sausville (National Cancer Institute, USA)
William G. Kaelin, Jr. (Howard Hughes Medical Institute, USA)
Choosing drug targets in the post-genomic era
2. Angiogenesis Inhibitors and Antimetastatic Agents
Chairpersons:
Jean P. Armand (Institut Gustave-Roussy, France)
Yutaka Ariyoshi (Aichi Hospital,
Japan)
10:05-10:30
Michael S. O’Reilly (Children’s Hospital, Boston, USA)
Tumor dormancy by angiogenesis suppression
10:30-10:55
Laura K. Shawver (Sugen, Inc., USA)
Small molecule inhibitors of receptor tyrosine kinases for anti-angiogenic therapy
10:55-11:10
Kenya Shitara (Kyowa Hakko Kogyo, Co. Ltd., Japan?j
Anti-VEGF receptor neutralizing antibody
11:10-11:35
Henrik S. Rasmussen (British Biotech Inc., USA)
Matrix metalloproteinase inhibition with marimastat - a novel anticancer strategy
11:35-11:50
Motowo Nakajima (Novartis Pharma K.K., Japan)
Anti-metastatic effects of a matrix metalloproteinase inhibitor CGS27023A
3-1. New Interesting Drugs under Clinical Consideration (Part 1)
Chairpersons:
Allen Oliff (Merck Research Laboratories, USA)
Takashi Tsuruo (University of Tokyo, Japan)
13:00-13:25
Allen Oliff (Merck Research Laboratories, USA)
Farnesyl transferase inhibitors as anticancer agents
13:25-13:50
Ivan D. Horak (Janssen Research Foundation, USA)
p21 Ras: A new target for therapeutic intervention
13:50-14:15
George R. P. Blackledge (Zeneca Pharmaceuticals, UK)
Clinical progress with the EGF receptor tyrosine kinase inhibitor, ZD1839
14:15-14:40
Alison Hannah (Sugen, Inc., USA)
SU101 - A novel signal transduction inhibitor and its effects on patients with a variety of tumors
14:40-14:55
Takao Yamori (Cancer Chemotherapy Center, Japan)
A novel DNA minor groove binder, MS-247: antitumor activity evaluated by in vitro and in vivo human cancer cell line panel
14:55-15:10
Manabu Suzuki (Ajinomoto, Co. Inc., Japan)
AC-7700, a novel combretastatin derivative, exerts strong antitumor effects through the selective decrease in tumor perfusion
15:10-15:25
Koji Murakami (Taiho Pharmaceutical, Co. Ltd., Japan)
Anti-tumor activity of TAC-101 against liver cancers and its mechanism of action
15:25-15:40
Discussion
15:40-16:10
Coffee Break
3-2. New Interesting Drugs under Clinical Consideration (Part 2)
Chairpersons:
Michael S. O’Reilly (Dana Farber Cancer Center, USA)
Noboru Horikoshi (Cancer Chemotherapy Center, Japan)
16:10-16:25
Noriyuki Masuda (Osaka Prefectural Habikino Hospital, Japan)
Overview of preclinical and clinical studies of Amrubicin
16:25-16:40
Tomohide Tamura (National Cancer Center Hospital, Japan)
Clinical trial of DX8951f
16:40-16:55
Nagahiro Saijo (National Cancer Center Hospital, Japan)
A topoisomerase II targetting new drug, NK109
16:55-17:20
Ross Donehower (Johns Hopkins Oncology Center, USA)
Phase I trials in the U.S. of TAS-103 and CS-682
17:20-17:35
Discussion
4. Current Status in New Drug Development in the US and Europe
Chairpersons:
Ross Donehower (Johns Hopkins Oncology Center, USA)
Haruo Sugano (Cancer Chemotherapy Center, Japan)
17:35-18:00
Edward A. Sausville (National Cancer Institute, USA)
New drugs at the NCI
18:00-18:25
Jean P. Armand (Institut Gustave-Roussy, France)
New drugs in France and Europe
18:25-18:30
Takashi Tsuruo (University of Tokyo, Japan)
Closing Remark
18:30-19:30
Mixer
